Preliminary Real-World Outcomes of Adjuvant Immunotherapy in Resected Esophageal Cancer: A Retrospective Study from Taiwan
Background: The CheckMate 577 trial demonstrated that adjuvant nivolumab improves disease-free survival in patients with resected esophageal cancer following neoadjuvant chemoradiotherapy. This study aimed to evaluate real-world outcomes associated with adjuvant immunotherapy. Methods: Patients...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Society for Thoracic & Cardiovascular Surgery
2025-07-01
|
| Series: | Journal of Chest Surgery |
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background: The CheckMate 577 trial demonstrated that adjuvant nivolumab improves
disease-free survival in patients with resected esophageal cancer following neoadjuvant
chemoradiotherapy. This study aimed to evaluate real-world outcomes associated with
adjuvant immunotherapy.
Methods: Patients with esophageal cancer and residual pathological disease who underwent
neoadjuvant therapy followed by surgical resection between January 2019 and
February 2024 were retrospectively analyzed. Participants were grouped by adjuvant treatment
received: no adjuvant therapy, adjuvant immunotherapy (AI), or adjuvant chemotherapy
(AC). Primary outcomes included overall survival (OS) and recurrence-free survival
(RFS). Subgroup analyses were performed for patients meeting CheckMate 577 eligibility
criteria and those with pathological node-positive (ypN+) status.
Results: The study included 127 patients (mean age: 60 years; male: 86%): 23 received AI,
36 AC, and 68 received no adjuvant therapy. There were no significant differences in OS
between AI and AC groups (median OS [mOS]: 34 months vs. 34 months; p=0.81), nor in
RFS (median RFS [mRFS]: 15 months vs. 16 months; p=0.94). In the CheckMate 577-eligible
subgroup (n=68), OS and RFS were similar between AI and AC groups (mOS: 25 months vs.
47 months; p=0.16; mRFS: 19 months vs. 20 months; p=0.74). Likewise, among ypN+ patients
(n=54), no significant differences in OS or RFS were noted between AI and AC (mOS:
34 months vs. 31 months; p=0.74; mRFS: 9.5 months vs. 14 months; p=0.89).
Conclusion: AI did not demonstrate a significant survival advantage compared to AC,
even in patients meeting CheckMate 577 criteria or those with ypN+ status. Identifying
the optimal adjuvant treatment for esophageal cancer remains a challenging and evolving
issue. |
|---|---|
| ISSN: | 2765-1606 2765-1614 |